Download PDF
Thromb Haemost 1985; 54(04): 833-837
DOI: 10.1055/s-0038-1660143
Original Article
Schattauer GmbH Stuttgart

The Effect of Pentosan Polysulphate (SP54) on the Fibrinolytic Enzyme System - A Human Volunteer and Experimental Animal Study

N A Marsh
The Department of Physiology, King‘s College, University of London, London, UK
,
P M Peyser
The Department of Physiology, King‘s College, University of London, London, UK
,
L J Creighton
*   The Division of Blood Products, National Institute for Biological Standards and Control, London, UK
,
M Mahmoud
*   The Division of Blood Products, National Institute for Biological Standards and Control, London, UK
,
P J Gaffney
*   The Division of Blood Products, National Institute for Biological Standards and Control, London, UK
› Author Affiliations
Further Information

Publication History

Received 04 February 1985

Accepted 23 September 1985

Publication Date:
19 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Pentosan polysulphate causes an increase in plasminogen activator activity in plasma both after oral ingestion and after subcutaneous injection. The effect is greatest after 3 h and has disappeared by 6 h. Repeat doses by mouth over 5 days elicit a similar response. The recorded increase in activity is due largely to the release of tissue-type plasminogen activator (tPA) from the endothelium according to the antigen assay although there could be a small contribution from Factor XH-related “intrinsic” fibrinolysis induced in vitro. SP54 enhances activity ex vivo by a non-specific surface effect, and this phenomenon may contribute the increased levels of activity seen in vitro. Administration of SP54 to animals elicits a similar increase in activator activity, the intramuscular route being slightly more effective. Results with an inferior vena cava thrombosis model in the rat suggest that pentosan polysulphate may induce a thrombolytic effect.

Key words

Pentosan polysulphate - Stimulation of fibrinolysis - Plasminogen activator - Rat thrombus model - Oral ingestion
 

  • References

  • 1 Halse Th. Aktivierung der Fibrinolyse und Thrombolyse durch Polysaccharidschwefelsaureester (Heparin, Heparinoide). Arzneim Forschung 1962; 12: 574-582
    PubMedSearch in Google Scholar
  • 2 Coccheri S, Gennari P, Loreti A. L“attivazione della fibrinolisi mediante polisaccaridi acidi. Clin Terap 1963; 25: 103-118
    PubMedSearch in Google Scholar
  • 3 Vinazzer H, Stemberger A, Haas S, Bliimel G. Influence of heparin; of different heparin fractions and of low molecular weight heparin-like substance on the mechanism of fibrinolysis. Thromb Res 1982; 27: 341-352
    CrossrefPubMedSearch in Google Scholar
  • 4 Marsh NA, Gaffney PJ. The effect of pentosan polysulphate (SP54) on the fibrinolytic system of man. Thromb Haemostas 1983; 50: 83 Abstr
    PubMedSearch in Google Scholar
  • 5 Klocking HP, Markwardt F. Pentosan-polysulphate-induced release of plasminogen activator. Haemostasis 1984; 14: 121
    PubMedSearch in Google Scholar
  • 6 Bergqvist D, Efsing HO, Hallbook T, Lindblad B. Prevention of postoperative thromboembolic complications. A prospective comparison between Dextran 70, Dihydroergotamin-Heparin and a sulphated polysaccharid. Acta Chir Scand 1980; 146: 559-568
    PubMedSearch in Google Scholar
  • 7 Bergqvist D, Ljungner H. A comparative study of Dextran 70 and a sulphated polysaccharide in the prevention of postoperative thromboembolic complications. Br J Surg 1981; 68: 449-454
    CrossrefPubMedSearch in Google Scholar
  • 8 Campani M. Farmaci attivatori della fibrinolisi. Minerva Chir 1963; 18: 1118-1127
    PubMedSearch in Google Scholar
  • 9 Menanteau A, Bruno M, Quilichini R, Nougarede M. Utilisation de l“heparinoide hemoclar dans le traitement des insuffisances cir-culatoires arterielles en neurologie (a propos de 78 cas). Marseille Med 1965; 192 no 11
    PubMedSearch in Google Scholar
  • 10 Viallefont H, Boudet C, Philippot M, Carrere M. Premiers resultats therapeutiques par l“Hemoclar en ophtalmologie. Bull Soc Ophtalm 1963; no 9-10
    PubMedSearch in Google Scholar
  • 11 Marangoni R, Ferrari A, Brera V. II trattamento dell“infarto miocar-dico con un farmaco attivatore della fibrinolisi (polisolfoestere del pentosano SP54) per infusione venosa lenta. Minerva Cardioangiol 1967; 15: 45-50
    PubMedSearch in Google Scholar
  • 12 Vinazzer H. Clinical and experimental data on the fibrinolytic action of pentosan polysulphate. Haemostasis 1984; 14: 122
    PubMedSearch in Google Scholar
  • 13 Fischer AM, Merton RE, Marsh NA, Williams S, Gaffney PJ, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate and heparin II: Effects of subcutaneous injection. Thromb Haemostas 1982; 47: 109-113
    PubMedSearch in Google Scholar
  • 14 Doutremepuich C, Gestreau JL, Maury MO, Quilichini R, Boisseau MR, Toulemonde F, Vairel E. Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction. Haemostasis 1983; 13: 109-112
    PubMedSearch in Google Scholar
  • 15 Clark RG, Robinson ICAF. A system for long-term infusions in conscious rats. J Physiol 1984; 350: 2P
    PubMedSearch in Google Scholar
  • 16 Nilsson IM, Olow B. Fibrinolysis induced by streptokinase in man. Acta chir Scand 1962; 123: 247-266
    PubMedSearch in Google Scholar
  • 17 Marsh NA. Measurement of fibrinolytic capacity by the euglobulin lysis time method - a problem of “units”. Thromb Res 1977; 12: 197-200
    PubMedSearch in Google Scholar
  • 18 Marsh NA, Arocha-Pinango CL. Evaluation of the fibrin plate method for estimating plasminogen activators. Thrombos Diathes Haemorrh 1972; 28: 75-88
    PubMedSearch in Google Scholar
  • 19 Gaffney PJ, Curtis AD. A collaborative study of a proposed International Standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
    PubMedSearch in Google Scholar
  • 20 Kluft C. Studies on the fibrinolytic system in human plasma: quantitative determination of plasminogen activators and proactivators. Thromb Haemostas 1979; 41: 365-383
    PubMedSearch in Google Scholar
  • 21 Rijken DC, Juhan-Vague I, de Cock F, Collen D. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med 1983; 101: 274-284
    PubMedSearch in Google Scholar
  • 22 Sampol J, Angles Cano E, Diner H, Benchimol P, Blachere A, Sultan Y. Effects of intravenous administration of pentosane polysulphate (Hemoclar) on coagulation and fibrinolysis in volunteers. Haemostasis 1984; 14: 121
    PubMedSearch in Google Scholar
  • 23 Keber D, Stegnar M, Keber I, Accetto B. Influence of moderate and strenuous daily physical activity on fibrinolytic activity of blood: possibility of plasminogen activator stores depletion. Thromb Haemostas 1979; 41: 745-755
    PubMedSearch in Google Scholar
  • 24 Astrup T, Rosa AT. A plasminogen proactivator-activator system in human blood effective in absence of Hageman factor. Thromb Res 1974; 4: 609-613
    CrossrefPubMedSearch in Google Scholar
  • 25 Marsh NA, Gaffney PJ. Exercise-induced fibrinolysis - fact or fiction. Thromb Haemostas 1982; 48: 201-203
    PubMedSearch in Google Scholar
  • 26 Marsh NA, Gaffney PJ. Some observations on the release of extrinsic and intrinsic plasminogen activators during exercise in man. Haemostasis 1980; 9: 238-247
    PubMedSearch in Google Scholar
  • 27 Marsh NA. Fibrinolysis. 1981. John Wiley and Sons; Chichester:
    Search in Google Scholar
  • 28 Jansen JWCM, Olieberg HH. The influence of several anaesthetics on the diluted blood clot lysis test of the rat. In: Progress in Fibrinolysis Davidson JF, Donati MB, Coccheri S. (Eds) Vol VII Churchill Livingstone, Edinburgh: 1985: 164-166
  • 29 Sandritter W, Schliiter G, Koppel G. Thrombolyse im Tierexperi-ment. Untersuchungen mit einen Polysaccharidsulfoester und Streptokinase. Med Welt 1964; 51: 2732-2739
    PubMedSearch in Google Scholar
  • 30 Fitzgerald DE, Szeto ILE, Spero J, Lewis JH. The thrombolytic effect of heparin and a heparin-like substance, SP54. Thrombos Diathes Haemorrh 1967; 17: 418-422
    PubMedSearch in Google Scholar
  • 31 Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh NA, Gaffney PJ. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-224
    CrossrefPubMedSearch in Google Scholar